If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Total Voting Rights

28 Feb 2022 11:12

RNS Number : 0358D
IQ-AI Limited
28 February 2022
 

28 February 2022

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Total Voting Rights

 

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 182,621,390.

 

This figure of 182,621,390 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

The Directors of the Company accept responsibility for the contents of this announcement

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBKFBDDBKDDBB
Date   Source Headline
20th Nov 20209:00 amRNSPrice Monitoring Extension
17th Nov 20201:26 pmRNSDirector/PDMR Shareholding
13th Nov 202011:05 amRNSSecond Price Monitoring Extn
13th Nov 202011:00 amRNSPrice Monitoring Extension
12th Nov 20204:41 pmRNSSecond Price Monitoring Extn
12th Nov 20204:36 pmRNSPrice Monitoring Extension
12th Nov 20202:01 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSCorrection: Director Dealing and CLN Conversion
11th Nov 20207:00 amRNSDirector Dealing and Conversion of Loan Notes
10th Nov 20204:35 pmRNSPrice Monitoring Extension
10th Nov 20202:06 pmRNSSecond Price Monitoring Extn
10th Nov 20202:00 pmRNSPrice Monitoring Extension
10th Nov 202011:06 amRNSSecond Price Monitoring Extn
10th Nov 202011:01 amRNSPrice Monitoring Extension
9th Nov 20202:06 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 202011:05 amRNSSecond Price Monitoring Extn
9th Nov 202011:00 amRNSPrice Monitoring Extension
9th Nov 20209:05 amRNSSecond Price Monitoring Extn
9th Nov 20209:00 amRNSPrice Monitoring Extension
9th Nov 20207:00 amRNSIB and the Mayo Clinic enter into an Agreement
6th Nov 20204:35 pmRNSPrice Monitoring Extension
6th Nov 20202:05 pmRNSSecond Price Monitoring Extn
6th Nov 20202:00 pmRNSPrice Monitoring Extension
6th Nov 202011:05 amRNSSecond Price Monitoring Extn
6th Nov 202011:00 amRNSPrice Monitoring Extension
5th Nov 20204:41 pmRNSSecond Price Monitoring Extn
5th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Nov 20209:00 amRNSPrice Monitoring Extension
5th Nov 20207:00 amRNSMontgomery Cancer Center Purchases IB's Software
4th Nov 20207:00 amRNSLSN Software Receives FDA Clearance
30th Oct 202011:05 amRNSSecond Price Monitoring Extn
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNS"Gad Free" Imaging moves to Validation Testing
15th Oct 20207:00 amRNSIB Stroke
8th Oct 20203:41 pmRNSStoneChecker Update
24th Sep 202010:43 amRNSThe Benefits and Significance of IB Neuro
16th Sep 20207:00 amRNSKeck Medical Centre of USC Purchases IB's Software
10th Sep 20207:00 amRNSIB Trax™
4th Sep 20209:03 amRNS“Gad Free” Imaging - One Step Closer
7th Aug 20207:00 amRNSHalf-year Report
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 202011:05 amRNSSecond Price Monitoring Extn
5th Aug 202011:00 amRNSPrice Monitoring Extension
5th Aug 20209:53 amRNSStonechecker Update
27th Jul 20207:00 amRNSUpdate - IB Stroke
10th Jul 20207:00 amRNSNew Development Aims to Detect Tumor Infiltration
19th Jun 20207:00 amRNSIB, the Recognised National Standard in MRI DSC
15th Jun 202011:52 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.